Skip to main content
Premium Trial:

Request an Annual Quote

New InforMax Chief Says Marketing, Not R&D, Will Take Center Stage First

NEW YORK, March 14 - Calling his move to InforMax a "no-brainer," Andrew Whiteley, the company's newly appointed president, chairman, and CEO, said he is excited about the future of bioinformatics and plans immediately to bolster his company's marketing efforts.

 

Speaking to investors and journalists in a conference call on Thursday morning, Whiteley said he has given himself 90 days to assess the company and flesh out his leadership strategy as he prepares to move into Alex Titomirov's old office on April 1. 

"We're very focused at developing what I call a robust product strategy in software and services" that help the company become profitable in the future, said Whiteley. "Certainly we need to strengthen [the marketing side] of the organization, and we will be seeking to do that."

He said that J Rollins, vice president of sales and marketing, "continues to do a great job for us in managing the sales group." But on the marketing side, Whiteley stressed that "we need to fill a position ... at a senior level in order to really progress. It's not been a functional part of InforMax so far, but I certainly intend to make it so."

 

Plans for R&D were a bit murkier. Asked to describe his strategy for the product side of the business, Whiteley said that InforMax must ensure that "charting a path to profitability ... we've got to ensure that we're balancing the investment we're making in R&D in a way that's sustainable in the context of our sales."

 

Asked by GenomeWeb about the likelihood of hiring new bioinformaticists or opening new R&D facilities in the short term, John Green, COO and CFO interjected and said: "We're always looking to continue to upgrade ... [our R&D group]. We have a lot of interest from really top talent" to join the company.

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.